Company news
Ocumension Therapeutics news in 2026
Ocumension Therapeutics's news releases, calls and decks from 2026, newest first.
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2026
November 4, 2026
Voluntary announcement NMPA approval for localized production of fluocinolone acetonide intravitreal implant
October 27, 2026
Inside information announcement topline results of the Month 36 primary analysis of the global multi-centre phase III clinical trial of OT-101 (0.01% atropine sulfate eye drops)
October 19, 2026
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2026
October 6, 2026
2026 Interim Report
September 24, 2026